Legal Discourse of United States Pharmaceutical Industry Mandatory License and Trips Agreement Post Doha Declaration
Abstract
The public health crisis related to HIV/AIDS, Tuberculosis and Malaria, was the starting point for the World Trade Organization (WTO) Ministerial Conference in 2001 which adopted the Doha Declaration on the TRIPS (Trade-Related Aspects of Intellectual Property Rights) and Public Health Agreements. The pharmaceutical industry as one of the knowledge driven sectors especially pharmaceutical research is very expensive and unpredictable. Making the patent system as a legal protection tool to facilitate innovation related to pharmaceutical products. The similarities between United States patent law and the TRIPS agreement also demonstrate United States’s influence in setting intellectual property standards globally. This research is a juridical-normative research using a statutory approach. The data collection technique was carried out by means of a literature study. Data analysis technique: qualitative normative analysis. The results showed that the United States' dissatisfaction with the level of intellectual property protection provided by the TRIPS agreement encouraged the development of the provisions of the TRIPS-Plus agreement in the United States Free Trade Area (FTA). The terms of the TRIPS-Plus agreement appear to be designed to negate the effective use of mandatory licensing by blocking the marketing of third-party drugs during the term of the patent. However, the TRIPS agreement retains some flexibility for World Trade Organization members, such as the data exclusivity and mandatory licensing outlined in the Doha Declaration.
Keywords
Full Text:
PDFReferences
Books
Permanand G. (2006). Eu Pharmaceuticals Regulation: The Politics Of Policy-Making. Manchester: Manchester University Press.
Case Law
Roche Products, Inc. Appellant, v. Bolar Pharmaceutical Co., Inc., Appellee, 733 F.2d 858 (Fed. Cir. 1984)
Documents
United Nations Development Programme. (2015). Guidelines for the examination of patent applications relating to pharmaceuticals. New York: United Nations.
Journals
Aaron Xavier Fellmeth. (2004). Secrecy, Monopoly, And Access To Pharmaceuticals In International Trade Law: Protection Of Marketing Approval Data Under The Trips Agreement. Harvard International Law Journal 45 (2).
Adam R. Young. (2009). Generic Pharmaceutical Regulation In The United States With Comparison To Europe: Innovation And Competition. Washington University Global Studies Law Review 8 (1).
Alan O. Sykes. (2002). Trips, Pharmaceuticals, Developing Countries, And The Doha “Solution.” Chi. J. Int’l L. 3 (47).
Antony Taubman. (2008). Rethinking Trips: ‘Adequate Remuneration’ For Non-Voluntary Patent Licensing. Journal of International Economic Law 11 (927).
Arnaldo Lacayo. (2002). Seeking A Balance: International Pharmaceutical Patent Protection, Public Health Crises, And The Emerging Threat Of Bio-Terrorism. University of Miami Inter-American Law Review 33 (295).
Barizah, Nurul. (2017). The development of ASEAN's intellectual property rights law; From Trips compliance to harmonization." Indonesia. Law Review 7.
Bartelt, Sandra. (2003). Compulsory licences pursuant to TRIPS article 31 in the light of the Doha Declaration on the TRIPS Agreement and public health. J. World Intell. Prop. 6.
Caroline Manne. (2010). Note, Pharmaceutical Patent Protection And Trips: The Countries That Cried Wolf And Why Defining “National Emergency” Will Save Them From Themselves. The George Washington International Law Review 42 (349).
Daniels, N., (2001). Justice, health, and healthcare. American Journal of Bioethics, 1(2).
Donald Harris. (2011). Trips After Fifteen Years: Success Or Failure, As Measured By Compulsory Licensing. The John Marshall Review of Intellectual Property Law 18 (367).
Ellen ‘T Hoen. (2002). Trips, Pharmaceutical Patents, And Access To Essential Medicines: A Long Way From Seattle To Doha. Chicago Journal of International Law 3 (27).
Erika George. (2011). The Human Right to Health and HIV/AIDS: South Africa and South-South Cooperation to Reframe Global Intellectual Property Principles and Promote Access to Essential Medicines. Indiana Journal of Global Legal Studies 18 (1).
Ekmekci, Perihan Elif, and Berna Arda. (2015). Enhancing John Rawls's theory of justice to cover health and social determinants of health. Acta Bioethica 21 (2).
FM‘t Hoen, E., Veraldi, J., Toebes, B. and Hogerzeil, H.V. (2018). Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016. Bulletin of the World Health Organization, 96 (3)
Frederick M. Abbott & Jerome H. Reichman. (2007). The Doha Round’s Public Health Legacy: Strategies For The Production And Diffusion Of Patented Medicines Under The Amended Trips Provisions. Journal of International Economic Law 10 (921).
Frederick M. Abbott. (2003). Non-Violation Nullification Or Impairment Causes Of Action Under The Trips Agreement And The Cancun Ministerial Conference: A Warning And Reminder, Quno Occasional Paper 11.
Jarrod Tudor. (2013). Compulsory Licensing in the European Union. George Mason Journal of International Commercial Law 4.
Jeffery Atik & Hans Henrik Lidgard, (2014). Embracing Price Discrimination: Trips And The Suppression Of Parallel Trade In Pharmaceuticals. University of Pennsylvania Journal of International Law 27 (4).
Joan Costa-Font. (2002). An Overview Of Progress In The International Regulation Of The Pharmaceutical Industry. Pierce Law Review 1 (1).
Kolawole A. (2012). Patent Rights And Essential Medicines In Developing Countries: Is Access Compromised For Innovation In Nigeria. Journal Of Medicine And Medical Sciences 3 (3).
Laura Chung. (2010). Use Of Paragraph 6 System For Access To Medicine. North Carolina Journal of International Law 36 (137).
M. Mcgill. (2009). Compulsory Licensing Of Patented Pharmaceuticals: Why A Wto Administrative Body Should Determine What Constitutes A Public Health Crisis Under The Doha Declaration. Wake Forest Intellectual Property Law Journal 10 (69).
Mariana Moto Prado. (2013). The Debatable Role of Courts in Brazil’s Health Care System: Does Litigation Harm or Help?. Journal of Law, Medicine & Ethics 41 (1).
Naomi A. Bass. (2002): 191. Implication of the TRIPS Agreement for Developing Countries: Pharmaceutical Patent Laws in Brazil and South Africa in the 21st Century. George Washington International Law Review 34 (2).
Naval Satarawala Chopra & Dinoo Muthappa, (2012). The Curious Case of Compulsory Licensing in India. Competition Law International 8 (2).
Nazura A. , Rohimi S. , Pardis M., Ahmad A. (2016). Protecting R&D Inventions Through Intellectual Property Rights. Journal of Intellectual Property Rights 21 (1).
Oke, Emmanuel Kolawole. (2005). Expanding The Reach Of India's 'Bolar' Exemption. Queen Mary Journal Of Intellectual Property 5 (4).
Pedro Roffe & Christoph Spennemann. (2006). The Impact Of Ftas On Public Health Policies And Trips Flexibilities. International Journal of Intellectual Property Management 1 (75).
Putri Dinda Dwi. Prohibition of Exporting Nickel Ore to The European Union in International Trade Law Perspective. Activa Yuris: Jurnal Hukum, Volume 1 Nomor 1 February 2021.
Stephen Gorove,. (1980). The 1980 Session Of The U.N. Committee On The Peaceful Uses Of Outer Space: Highlight Sof Positionson Outstanding Legal Issues. Journal of Space Law 8 (174).
Sigratama Akbar et al. Judicial overview on criminal liability against a person who deliberately use, sell or export an industrial design without getting approval from the exclusive rightholders of industrial design based on industrial design law. Activa Yuris: Jurnal Hukum, Volume 1 Nomor 1 February 2021.
Susan K. Sell. (2002); 13. Trips And The Access To Medicines Campaign. Wisconsin International Law Journal 20 (481).
T Hoen, E., (2002). TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha. Chicago Journal of International Law 3.
Tomi Suryo Utomo. (2007). Deklarasi Doha Dalam Perspektif Obat Murah Dan Terjangkau: Sebuah Pelengkap Perjanjian Trips, Jurnal Unisia 30 (64).
Totok Mradiyanto. (2002). Hukum Paten Indonesia Dalam Perspektif Kepentingan Konsumen Untuk Akses Obat. Perencanaan Pembangunan 1 (27).
Umar R. Bakhsh. (2012). The Plumpy’Nut Predicament: Is Compulsory Licensing a Solution. Chicago-Kent Journal of Intellectual Property 11 (72).
Vera Zolotaryova. (2008). Are We There Yet? Taking ‘TRIPS’ to Brazil and Expanding Access to HIV/AIDS Medication. Brooklyn Journal of International Law 33 (1).
Vipin M. (2012). Patenting Of Pharmaceuticals: An Indian Perspective. International Journal Of Drug Development & Research 4 (3).
Vitaliy M. Pashkov et al. (2016). The Impact Of The Legal Regime Of Intellectual Property Protection In The Pharmaceutical Market. Journal Wiadomości Lekarskie 20 (3).
Worden, D.E. (1995). The drive toward regulatory harmonization: what is harmonization and how will it impact the global development of new drugs?. Drug information journal, 29
Regulations
The Code of Federal Regulations
The Drug Price Competition and Patent Term Restoration Act of 1984
The Food, Drug, and Cosmetic Act of 1938
The Trade Act of 1974
The United States Antitrust Laws
The United States Constitution
Websites
Federal Digital System. About Code Of Federal Regulations,” accessed April 27, 2021, Http://Www.Gpoaccess.Gov/Cfr/ About.Html
Ministry of Public Health and the National Health Security Office, “The 10 Burning Questions on the Government Use of Patents on the Four Anti-Cancer Drugs in Thailand”, accessed April 27, 2021, http://www.moph.go.th/hot/ Second_white_paper_on_the_Thai_CL_%5BEN%5D.pdf.
Organization For Economic Cooperation And Development, “Oecd Health Data 2002 4th Ed.” accessed April 27, 2021, Http://Www.Oecd.Org /En/Document/0,,En-Document-684-5-No-1-29046-0,00.Html, Akses 27 April 2021
Prat Boonyawongvirot, Permanent Secretary, Ministry of Public Health, “Announcement Regarding Exploitation of Patents on Drugs and Medical Supplies for Clopidogrel”, accessed April 28, 2021, http://www.cptech.org/ip/ health/c/thailand/thai-cl-clopidogrel_en.pdf.
Thawach Suntrajarn, Director General, Announcement of the Department of Disease Control, Ministry of Public Health, Thailand on the Public Use of Patent for Pharmaceutical Products,” accessed April 28, 2021, http://www.cptech.org/ip/health/ c/thailand/thaicl4efavirenz.html.
Thawach Suntrajarn, Director General, Decree of Department of Disease Control, Ministry of Public Heath, “Regarding Exploitation of Patent on Drugs and Medical Supplies by the Government on Combination Drug Between Lopinavir and Ritonavir”, accessed April 28, 2021, http://www.cptech.org/ip/health/c/thailand/thai-cl- kaletra_en.pdf.
Tracy Staton, “India to Hit Roche, BMS with Compulsory License on 3 Cancer Drugs,” FiercePharma, accessed April 28, 2021, http://www.fiercepharma.com/story/india-hit-roche-bms-compulsory-licenses-3-cancer-drugs.
Article Metrics
Abstract has been read : 390 timesPDF file viewed/downloaded: 0 times
DOI: http://doi.org/10.25273/ay.v2i1.11878
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Wahyu Pratama Aji
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Office:
Program Studi Hukum, Fakultas Hukum, Universitas PGRI Madiun
email : activayuris@unipma.ac.id